ClinicalTrials.gg
CompletedNCT04489797Updated Oct 30, 2020

A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants

A Phase 1 interventional study of Acalabrutinib and Rabeprazole in Infectious Disease, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-30.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2020, 6 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 161 studies in Communicable Diseases with a site in United States — 29 open to participants now, 43 under way, none of them phase 3. Communicable Diseases · United States.

Enrollment
82nd of 115
35 · median 78
Started
2020
with 15 others
Phase 1
20 of 161
1 open now
Registered
100th of 161
by date

Among the 161 studies in Communicable Diseases with a site in United States, this one is the 82nd largest by enrollment of the 115 interventional ones that give a count, is one of 16 that started in 2020, is one of 20 in phase 1, and was the 100th registered.

Communicable Diseases

627 studies on the registry are indexed under Communicable Diseases; 128 are open to participants now.

Browse Communicable Diseases studies →

Open to participants now

29 of the 161 studies in Communicable Diseases with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 91 Communicable Diseases studies recruiting now, 49 (54%) set no upper age limit and 32 (35%) stop at 75 or younger; 35 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Communicable Diseases with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted to support the clinical development of acalabrutinib in participants who need treatment with proton pump inhibitors while taking acalabrutinib.

Read the detailed description

This is an open-label, single-center, randomized study in healthy participants to evaluate the effect of proton-pump inhibitors (rabeprazole; PPI) on acalabrutinib 100-mg capsule dosed orally with COCA-COLA. Participants will receive a single dose of acalabrutinib alone or with rabeprazole, and pharmacokinetic (PK), safety and tolerability will be assessed.

03

Conditions studied

  • Infectious Disease

Browse trials for

Keywords

  • Pharmacokinetics
  • Bioavailability
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed .
  • Male participants and their female partners/spouses must adhere to the methods.
  • Female participants must have a negative pregnancy test at screening, must not be lactating, and must be of non-, confirmed at screening by fulfilling one of the following criteria:

    • defined as amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments and follicle stimulating hormone levels in the postmenopausal range.
    • Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not bilateral tubal ligation.
  • Have a between 18.5 and 30 kg/m\^2, inclusive, and weigh at least 50 kg and no more than 100 kg, inclusive, at screening.
  • Understands the study procedures in the informed consent form and willing and able to comply with the protocol.

Exclusion criteria

Exclusion Criteria:

  • History or presence of any disease (including active coronavirus disease 2019 infection).
  • History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically significant illness, medical/surgical procedure, or trauma within 30 days of the first administration of medicinal product (IMP).
  • Any clinically significant abnormalities in hematology, coagulation, clinical chemistry, or urinalysis results, at screening defined as:

    • less than lower limit of normal.
    • Serum , aspartate aminotransferase, alkaline phosphatase or serum (total and direct) > 1.5 .
  • Any clinically significant abnormal findings in vital signs at screening (eg, systolic blood pressure [BP] \< 90 mmHg or ≥ 140 mmHg; diastolic BP \< 50 mmHg or ≥ 90 mmHg; pulse \< 50 or > 90 bpm).
  • Any clinically significant abnormalities on standard 12-lead at screening.
  • Any positive result on screening for serum surface antigen, hepatitis B, , and antibody.
  • Has received a new chemical entity within 90 days of the first administration of IMP in this study. The period of exclusion begins 90 days after the final dose or 30 days after the last visit whichever is the longest.
  • Plasma donation within 30 days of screening or any blood donation/loss more than 500 mL during the 90 days prior to screening.
  • History of severe allergy/ or ongoing allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to acalabrutinib or rabeprazole.
  • Current smokers or those who have smoked or used nicotine products within the 90 days prior to screening.
  • Positive screen for drugs of abuse or cotinine at screening.
  • Treatment with a strong cytochrome P450 3A () inhibitor (within 14 days before first administration of IMP) or strong CYP3A inducer (within 28 days before first administration of IMP).
  • Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 14 days prior to the first administration of IMP or longer if the medication has a long half-life. Hormonal replacement therapy will not be allowed.
  • Known or suspected history of alcohol or drug abuse, or excessive intake of alcohol.
  • Excessive intake of caffeine-containing drinks or food or would likely be unable to refrain from the use of caffeine-containing beverages during in-house stay at the Clinical Unit.
  • Involvement of any AstraZeneca, Acerta Pharma, Parexel or study site employee or their close relatives.
  • Judgment by the Investigator that the participant should not participate in the study if they have any ongoing or recent (ie, during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
  • Participants who cannot communicate reliably with the Investigator.
  • Vulnerable participants, eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
  • Inability to swallow acalabrutinib capsules.
  • Evidence of ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections). Note: Participants with localized cutaneous fungal infections are eligible.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Arm A

    Participants will receive single oral dose of acalabrutinib capsule with 100 mL of water.

    Drug: Acalabrutinib

  • Experimental
    Arm B

    Participants will receive single oral dose of acalabrutinib capsule taken with 100 mL of COCA-COLA along with 20 mg rabeprazole.

    Drug: Acalabrutinib · Drug: Rabeprazole

Interventions

  • Participants will receive single oral dose of acalabrutinib on day 1 as per the arms they are randomized.

  • Participants will receive twice daily oral dose of 20 mg rabeprazole on days -3, -2, and -1.

06

What researchers measure

Primary outcomes

  1. Area under plasma concentration-time curve from time zero to infinity (AUCinf)

    Assessment of AUCinf for acalabrutinib and ACP-5862 (metabolite of acalabrutinib) following administration of capsule with and without rabeprazole.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on Day 1, and 24 hours post-dose on Day 2

  2. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUClast)

    Assessment of AUClast for acalabrutinib and ACP-5862 following administration of capsule with and without rabeprazole.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on Day 1, and 24 hours post-dose on Day 2

  3. Maximum observed plasma concentration (Cmax)

    Assessment of Cmax for acalabrutinib and ACP-5862 following administration of capsule with and without rabeprazole.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on Day 1, and 24 hours post-dose on Day 2

Secondary outcomes

  1. Number of participants with adverse events and serious adverse events

    Assessment of the safety and tolerability of acalabrutinib capsule when administered with COCA-COLA and rabeprazole.

    Time frame: From screening until Follow-up visit (Upto 5 to 6 Weeks)

07

Study locations

1 site
  • Research Site
    Anaheim, California 92801, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Aug 2020, 1 month.

Of 25 phase 1 interventional studies under Communicable Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2020
First posted
Jul 28, 2020
StartActual
Jul 20, 2020
Primary completionActual
Aug 28, 2020
CompletionActual
Aug 28, 2020
Last update
Oct 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04489797
Lead sponsor
AstraZeneca
Collaborators
Acerta Pharma BV
Responsible party
Sponsor
First posted
Jul 28, 2020
Start date
Jul 20, 2020
Primary completion
Aug 28, 2020
Completion
Aug 28, 2020
Last update
Oct 30, 2020

Study contacts

Peter J. Winkle, MD FACP FACG CPI
principal investigator · Anaheim Clinical Trials

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion